Detection of Minimal Residual Disease (MRD)

in Acute Lymphoblastic Leukemia


Acute lymphoblastic leukemia (ALL)  is the most frequent malignant disease in children. The success of treatment is dependent on permanent elimination of leukemic cells below microscopic detection limit.

The standard method for the investigation of BCR-ABL negative ALL is the detection of patient’s leukaemia specific somatically rearranged immunoglobuline (Ig-) and T-cell receptor (TCR) genes.
The procedure is divided into two steps:

    • Characterization of junctional sequences and design of complementary PCR-primer
    • MRD detection in follow-up samples by means of quantitative PCR
    • Required sample material:
      One initial diagnostic sample of the leukemia (as reference).
      5 ml EDTA-BM or 10 ml EDTA-PB is necessary.
      The results of the follow-up analysis (log-reduction compared with reference sample) are available on average 2-4 working days after receipt of the sample.